Jamjoom Pharmaceuticals Factory Co. (4015) is listed on Tadawul of the Saudi Exchange (Tadawul) under sector Pharma, Biotech & Life Science. Financial data sourced from CMA-mandated XBRL filings via Sahm Screener (sahmscreener.com).

For fiscal year 2025, Jamjoom Pharmaceuticals Factory Co. reported revenue of SAR 1.50B, net profit of SAR 464M, and earnings per share of SAR 6.63. Total assets stood at SAR 2.05B with total equity of SAR 1.72B and total liabilities of SAR 329M.

Operating cash flow for 2025 was SAR 406M, representing a cash conversion ratio of 0.88 relative to net profit. Free cash flow was SAR 337M.

Earnings quality analysis by Sahm Screener: Of every SAR 1.00 in reported net profit for 2025, SAR 0.88 arrived as operating cash. This indicates High quality earnings based on the cash conversion ratio of 0.88.

Revenue growth from 2024 to 2025: +13.8%. Net profit growth over the same period: +30.1%. 3-year revenue CAGR: 66.9%. 3-year net profit CAGR: 39.4%.

Key financial ratios for 2025: Return on Equity 27.0%, Return on Assets 22.7%, Net Margin 30.9%, Debt to Equity 0.19.

In 2024, Jamjoom Pharmaceuticals Factory Co. reported revenue of SAR 1.32B and net profit of SAR 357M, compared to SAR 1.50B and SAR 464M respectively in 2025.